HSP up +1.34% percent right now. $HSP High is at 56.76 and

New Post Public Reply Private Reply Replies (0) Message Board
Lucky Jimmy
HSP up +1.34% percent right now. $HSP High is at 56.76 and the Low 55.81 with current volume of 493,833.

Recent News posted below.

HSP Hospira Inc Recent Headline News

Hospira Inc.'s Third-Quarter Earnings: The 3 Key Takeaways
Leo Sun, The Motley Fool - Motley Fool - Fri Nov 07, 10:53AM CST
Shares of Hospira jumped nearly 7% on Nov. 6 after the maker of injectable drugs and infusion technologies reported impressive third-quarter earnings. Source: Wikimedia Commons. Hospira's revenue climbed 2% year over year to $1.2 billion,...
HSP: 56.97 (+0.99)

Stock Market News for November 07, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 9:10AM CST
Benchmarks ended in the green zone yesterday following ECB President Mario Draghi’s statement regarding possible expansion of monetary stimulus by the European Central Bank
DHI: 24.02 (+0.59), WFM: 47.23 (-0.82), TSLA: 251.08 (+9.15), LEN: 46.60 (+1.31), QCOM: 69.79 (+0.43), PHM: 20.94 (+0.63), TOL: 33.64 (+0.69), GNW: 8.30 (+0.18), HSP: 56.97 (+0.99)

Strength Seen in Hospira (HSP): Stock Moves 6.7% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 8:25AM CST
Hospira (HSP) was a big mover last session, with shares rising nearly 7% on the day.
ICUI: 81.23 (+9.42), ABAX: 53.68 (+0.74), GWPH: 74.60 (+0.65), HSP: 56.97 (+0.99)

Look for Shares of Hospira to Potentially Pullback after Yesterday's 6.67% Rise
Comtex SmarTrend(R) - Thu Nov 06, 4:13PM CST
Hospira (NYSE:HSP) traded in a range yesterday that spanned from a low of $55.00 to a high of $58.00. Yesterday, the shares gained 6.7%, which took the trading range above the 3-day high of $53.88 on volume of 3.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
HSP: 56.97 (+0.99)

Watch for Hospira to Potentially Pullback After Gaining 6.67% Yesterday
Comtex SmarTrend(R) - Thu Nov 06, 4:13PM CST
Hospira (NYSE:HSP) traded in a range yesterday that spanned from a low of $55.00 to a high of $58.00. Yesterday, the shares gained 6.7%, which took the trading range above the 3-day high of $53.88 on volume of 3.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
HSP: 56.97 (+0.99)

Hospira Beats on Earnings & Sales in Q3, Narrows Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 1:53PM CST
Hospira reported third-quarter 2014 adjusted earnings of 74 cents per share.
AGN: 195.84 (+0.60), ABAX: 53.68 (+0.74), ABBV: 63.66 (-0.13), HSP: 56.97 (+0.99)

Hospira (HSP) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Thu Nov 06, 12:39PM CST
The following Hospira (HSP) conference call took place on November 6, 2014, 09:00 AM ET. This is a transcript of that earnings call:
HSP: 56.97 (+0.99)

Hospira's (HSP) CEO Michael Ball on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 12:20PM CST

HSP: 56.97 (+0.99)

Hospira Q3 income up big
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 8:11AM CST

HSP: 56.97 (+0.99)

Hospira (HSP) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Nov 06, 7:55AM CST

HSP: 56.97 (+0.99)

Hospira unveils generic Paricalcitol Injection in three multi-dose sizes
M2 - Thu Nov 06, 7:28AM CST
Injectable drug company
Scroll down for more posts ▼

Top 10 Most Recent News Articles

What to Expect: Your First Therapy Session Insights

Updated Category News Views 169

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Continue Reading
Bio-Thera's New Data: A Game Changer for NSCLC?

Updated Category News Views 337

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...

Continue Reading
TORRAS Stands Tall with iPhone 18 Pro Cases

Updated Category News Views 191

TORRAS Shines in Magnetic Stand Case Evaluation In the whirlwind of smartphone accessories, where the battle lines are drawn between protection and functionality, TORRAS has emerged victorious with its magnetic stand cases for the iPhone 18 Pro and its beefier brother, the iPhone 18 Pro Max. Expert Consumers—a trusted name in product evaluations—has given TORRAS the...

Continue Reading
CapCut's AI Tools Reshape Video Content Creation

Updated Category News Views 143

AI Revolution in Marketing Content: CapCut Takes Lead It's like the old guard of marketing has hitched a ride on a rocket. In 2026, CapCut has stomped into the limelight with Better Business Advice giving them a nod for their prowess in AI-driven content creation. This isn't some passing trend; it's a seismic shift in how businesses craft their messages. CapCut ain't just...

Continue Reading
World Young Scientist Summit 2026 in Wenzhou Kicks Off

Updated Category News Views 154

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Continue Reading
Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Updated Category News Views 352

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Continue Reading
Likang's Bold Move: Cancer Immunotherapy at AD Summit

Updated Category News Views 134

Cancer Care Takes Center Stage Kicking off with a bang in Abu Dhabi, Likang Life Sciences has made a splash in the world of personalized cancer immunotherapy. The Abu Dhabi Future Health Summit 2026 served as the backdrop for this bold move, lighting up discussions with their AI-enabled innovations. Likang's showing at the Summit wasn't just another walk in the park—it...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 0

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
ST Engineering iDirect, MBSat Forge Middle East Satellite Hub

Updated Category News Views 37

Satellite Services Take Off in the Middle East Never thought the day would come where the Middle East is on the threshold of leapfrogging satellite tech, but here we are. ST Engineering iDirect just locked arms with MBSat—yep, that's part of the Mohammed Al Barwani Group—to birth a next-gen satellite connectivity service hub in Oman and across surrounding areas....

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 163

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading

Top 5 Most Recently Viewed Articles

BerGenBio Welcomes First Patient in Lung Cancer Study

Updated Category News Views 202

BerGenBio Embarks on Promising Lung Cancer Trial BerGenBio ASA, a clinical-stage biopharmaceutical company dedicated to combating serious diseases through innovative therapies, has reached a significant milestone in its journey. The company has successfully included the first patient in its clinical trial, focusing on the cutting-edge AXL kinase inhibitor known as...

Continue Reading
CIMG Inc. Introduces Tokenized Stock on FlowStocks Platform

Updated Category News Views 247

CIMG Inc. Introduces Tokenized Stock on FlowStocks Platform CIMG Inc. (NASDAQ: IMG), a dynamic group in the digital health and sales development sector, has officially launched its tokenized stock on the FlowStocks platform. This exciting development follows successful testing and represents a significant shift in how the company interacts with its investors. The new...

Continue Reading
Exploring the Impact of New SEC Leadership on Cryptocurrency

Updated Category News Views 179

New Era for Cryptocurrency Under SEC Leadership The recent changes at the Securities and Exchange Commission (SEC) under new leadership signal a transformative period for the cryptocurrency market. These developments could reshape the regulatory landscape, offering clarity and direction for investors and companies involved in the digital asset space. Understanding the...

Continue Reading
Shytoshi Kusama Transitions Roles: Shiba Inu's New Direction

Updated Category News Views 190

Shytoshi Kusama Transitions to New Leadership Role Shytoshi Kusama, the driving force behind the Shiba Inu ecosystem, has made a significant change by stepping down from his role as the lead visionary. This pivotal shift marks a transition to the position of lead ambassador, as he aims to spearhead global adoption more effectively. The Shift in Leadership Announcing his...

Continue Reading
BASF Shares Fall Following Proposed Dividend Cuts to Shareholders

Updated Category News Views 281

BASF (ETR:BASFN) just took a hit on its stock price after announcing some major shifts in its dividend policy. Shares plummeted by 2.9% to €44.035, all thanks to the company's new proposed minimum annual dividend of €2.25 per share for the upcoming 2024 business year. That’s a stark drop from the previous €3.40 per share they dished out in 2023—talk about making...

Continue Reading